|
Gene: ATP5J |
Gene summary for ATP5J |
Gene summary. |
Gene information | Species | Human | Gene symbol | ATP5J | Gene ID | 522 |
Gene name | ATP synthase peripheral stalk subunit F6 | |
Gene Alias | ATP5 | |
Cytomap | 21q21.3 | |
Gene Type | protein-coding | GO ID | GO:0002027 | UniProtAcc | P18859 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
522 | ATP5J | GSM4909281 | Human | Breast | IDC | 4.80e-16 | -3.97e-01 | 0.21 |
522 | ATP5J | GSM4909282 | Human | Breast | IDC | 2.12e-16 | -3.97e-01 | -0.0288 |
522 | ATP5J | GSM4909285 | Human | Breast | IDC | 1.08e-15 | -3.97e-01 | 0.21 |
522 | ATP5J | GSM4909286 | Human | Breast | IDC | 2.44e-15 | -3.97e-01 | 0.1081 |
522 | ATP5J | GSM4909287 | Human | Breast | IDC | 2.62e-21 | -3.97e-01 | 0.2057 |
522 | ATP5J | GSM4909288 | Human | Breast | IDC | 6.30e-05 | -3.97e-01 | 0.0988 |
522 | ATP5J | GSM4909289 | Human | Breast | IDC | 2.23e-03 | -3.97e-01 | 0.1064 |
522 | ATP5J | GSM4909290 | Human | Breast | IDC | 2.97e-15 | -3.97e-01 | 0.2096 |
522 | ATP5J | GSM4909291 | Human | Breast | IDC | 2.37e-12 | -3.97e-01 | 0.1753 |
522 | ATP5J | GSM4909293 | Human | Breast | IDC | 4.80e-16 | -3.97e-01 | 0.1581 |
522 | ATP5J | GSM4909294 | Human | Breast | IDC | 4.12e-17 | -3.97e-01 | 0.2022 |
522 | ATP5J | GSM4909295 | Human | Breast | IDC | 1.09e-09 | -3.97e-01 | 0.0898 |
522 | ATP5J | GSM4909296 | Human | Breast | IDC | 1.08e-15 | -3.97e-01 | 0.1524 |
522 | ATP5J | GSM4909297 | Human | Breast | IDC | 2.12e-16 | -3.97e-01 | 0.1517 |
522 | ATP5J | GSM4909298 | Human | Breast | IDC | 4.12e-17 | -3.97e-01 | 0.1551 |
522 | ATP5J | GSM4909299 | Human | Breast | IDC | 1.08e-15 | -3.97e-01 | 0.035 |
522 | ATP5J | GSM4909300 | Human | Breast | IDC | 1.54e-08 | -3.97e-01 | 0.0334 |
522 | ATP5J | GSM4909301 | Human | Breast | IDC | 4.12e-17 | -3.97e-01 | 0.1577 |
522 | ATP5J | GSM4909302 | Human | Breast | IDC | 5.30e-21 | -3.97e-01 | 0.1545 |
522 | ATP5J | GSM4909303 | Human | Breast | IDC | 1.27e-05 | -3.97e-01 | 0.0438 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05014210 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa05016210 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
hsa05012211 | Esophagus | ESCC | Parkinson disease | 201/4205 | 266/8465 | 1.56e-18 | 8.72e-17 | 4.46e-17 | 201 |
hsa05208211 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa05022210 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
hsa05010210 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
hsa05020210 | Esophagus | ESCC | Prion disease | 193/4205 | 273/8465 | 6.42e-13 | 1.34e-11 | 6.89e-12 | 193 |
hsa00190210 | Esophagus | ESCC | Oxidative phosphorylation | 104/4205 | 134/8465 | 2.04e-11 | 2.98e-10 | 1.53e-10 | 104 |
hsa05415211 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
hsa04714211 | Esophagus | ESCC | Thermogenesis | 163/4205 | 232/8465 | 9.22e-11 | 1.14e-09 | 5.86e-10 | 163 |
hsa0501438 | Esophagus | ESCC | Amyotrophic lateral sclerosis | 266/4205 | 364/8465 | 1.31e-20 | 2.20e-18 | 1.13e-18 | 266 |
hsa0501638 | Esophagus | ESCC | Huntington disease | 226/4205 | 306/8465 | 1.38e-18 | 8.72e-17 | 4.46e-17 | 226 |
hsa05012310 | Esophagus | ESCC | Parkinson disease | 201/4205 | 266/8465 | 1.56e-18 | 8.72e-17 | 4.46e-17 | 201 |
hsa05208310 | Esophagus | ESCC | Chemical carcinogenesis - reactive oxygen species | 168/4205 | 223/8465 | 1.83e-15 | 6.81e-14 | 3.49e-14 | 168 |
hsa0502238 | Esophagus | ESCC | Pathways of neurodegeneration - multiple diseases | 318/4205 | 476/8465 | 6.10e-15 | 2.04e-13 | 1.05e-13 | 318 |
hsa0501038 | Esophagus | ESCC | Alzheimer disease | 263/4205 | 384/8465 | 1.80e-14 | 5.47e-13 | 2.80e-13 | 263 |
hsa0502038 | Esophagus | ESCC | Prion disease | 193/4205 | 273/8465 | 6.42e-13 | 1.34e-11 | 6.89e-12 | 193 |
hsa0019038 | Esophagus | ESCC | Oxidative phosphorylation | 104/4205 | 134/8465 | 2.04e-11 | 2.98e-10 | 1.53e-10 | 104 |
hsa0541538 | Esophagus | ESCC | Diabetic cardiomyopathy | 146/4205 | 203/8465 | 5.81e-11 | 7.78e-10 | 3.99e-10 | 146 |
hsa04714310 | Esophagus | ESCC | Thermogenesis | 163/4205 | 232/8465 | 9.22e-11 | 1.14e-09 | 5.86e-10 | 163 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP5J | SNV | Missense_Mutation | novel | c.10N>A | p.Asp4Asn | p.D4N | P18859 | protein_coding | tolerated_low_confidence(0.18) | benign(0.005) | TCGA-E2-A10C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
ATP5J | SNV | Missense_Mutation | novel | c.10N>A | p.Asp4Asn | p.D4N | P18859 | protein_coding | tolerated_low_confidence(0.18) | benign(0.005) | TCGA-LL-A73Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | taxotere | SD |
ATP5J | SNV | Missense_Mutation | novel | c.290N>T | p.Thr97Ile | p.T97I | P18859 | protein_coding | deleterious(0.05) | possibly_damaging(0.481) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ATP5J | SNV | Missense_Mutation | rs140201687 | c.88N>T | p.Arg30Trp | p.R30W | P18859 | protein_coding | tolerated(0.08) | benign(0.019) | TCGA-AX-A06D-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | carboplatin | PD |
ATP5J | SNV | Missense_Mutation | c.115G>A | p.Ala39Thr | p.A39T | P18859 | protein_coding | tolerated(0.1) | probably_damaging(0.991) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD | |
ATP5J | SNV | Missense_Mutation | c.56N>A | p.Ser19Tyr | p.S19Y | P18859 | protein_coding | deleterious(0) | possibly_damaging(0.747) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ATP5J | SNV | Missense_Mutation | c.115G>A | p.Ala39Thr | p.A39T | P18859 | protein_coding | tolerated(0.1) | probably_damaging(0.991) | TCGA-BK-A0C9-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ATP5J | SNV | Missense_Mutation | c.185N>A | p.Arg62Gln | p.R62Q | P18859 | protein_coding | tolerated(0.32) | benign(0.083) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ATP5J | SNV | Missense_Mutation | novel | c.106A>C | p.Thr36Pro | p.T36P | P18859 | protein_coding | deleterious(0.01) | probably_damaging(0.915) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
ATP5J | SNV | Missense_Mutation | novel | c.271N>T | p.Gly91Cys | p.G91C | P18859 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-85-A4QQ-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |